16
Sep
2025
First CinCor, Now AllRock: Versant, Westlake Pump $50M Into PAH Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Sep
2025
Leveraging AI at the FDA—Product Reviews and Beyond
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Sep
2025
An IPO Revival, Novartis Buys Tourmaline, & Tribute to a Biology Pioneer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Sep
2025
Can Biopharma Make AI Sing?
“… When I’m with her I’m confused Out of focus and bemused And I never know exactly where I am Unpredictable as weather She’s as flighty as a feather She’s a darling, she’s a demon, she’s a lamb… … How do you solve a problem like Maria? How do you catch a cloud and pin it down?” The lyrics, of course, are... Read More
9
Sep
2025
Next Stop: Kilimanjaro 2026 for Damon Runyon Cancer Research
The biotech industry can do amazing things when focused on an audacious goal. Like curing cancer. I’m fired up to announce the next Timmerman Traverse for Damon Runyon Cancer Research Foundation. This group of 23 biotech executives and investors are training to hike up to the summit of Kilimanjaro, the highest peak in Africa (elev. 19,341 feet), in February 2026.... Read More
5
Sep
2025
Novartis CEO Vas Narasimhan: Drawn to Analytics, Grounded Expectations for AI
Yesterday, the MS/MBA program at Harvard Business School (HBS) hosted Novartis CEO Dr. Vas Narasimhan for what proved to be a captivating and wide-ranging discussion, led by Dr. Christiana Bardon (Managing Partner of MPM BioImpact) and Professor Amitabh Chandra of HBS and the Harvard Kennedy School. Chandra co-leads the MS/MBA program together with the former head of Novartis’s early research... Read More
4
Sep
2025
Atlas Adds $400M, Kite Buys In Vivo CAR-T Company, & AbbVie Bets on Psychedelics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Sep
2025
Corsera Health, Led by Maraganore and Meanwell, Aims to Prevent Heart Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Aug
2025
Creating Lower Cost, Accessible Cell & Gene Therapies: Jen Adair on The Long Run
Jen Adair is today’s guest on The Long Run. Jen is a professor and Vice Chair in the Department of Genetic and Cellular Medicine, and Associate Director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School. Her laboratory develops tools and methods for safe and effective delivery of gene therapy. In this conversation, you’ll hear... Read More
24
Aug
2025
Timmerman Traverse for Life Science Cares Raises Another $1.1M to Fight Poverty in 2025
Another Timmerman Traverse for Life Science Cares is in the books. This year, we raised $1.15 million from more than 1,000 donors to fight poverty in biotech hubs around the US. We raised awareness of worthy nonprofits close to home, through Life Science Cares. Perhaps most importantly, we had an unforgettable life experience, making friends amid some of the most... Read More
23
Aug
2025
Health on Tap
Mingling easily with the sold-out crowd of eager young professionals crowding into a Boston brewery last Thursday to hear a local historian unpack the Gilded Age, Ty and Felecia Freely laugh more and grimace less than prototypical health entrepreneurs. Yet they may be cultivating exactly the sort of engagement health tech too often overlooks — and on which flourishing and... Read More
20
Aug
2025
Seeking Pockets of Reducibility in Personalized Medicine: Lessons from Google’s AI Health Coach Study
Technologists often imagine a future of health in which AI delivers highly personalized, preemptive guidance, powered by dense, dynamic streams of data. Continuous sensors track physiology and metabolism; lab panels and -omics assays capture molecular signatures; imaging contributes structural and functional context; and genome sequencing rounds out the picture. Collected longitudinally and at population scale, these data are linked to... Read More
14
Aug
2025
OrbiMed’s Royalty Fund, Strand Advances IL-12 mRNA, & Melinta’s Turnaround
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2025
CAR-T Cells Against Solid Tumors: Sabah Oney on The Long Run
Sabah Oney is today’s guest on The Long Run. Sabah is the CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics. This startup is developing engineered CAR-T cell therapies for solid tumors. The goal is to bring the power of CAR-T cell cures to a wider group of patients, beyond those with blood cancers. Dispatch was founded by some of the... Read More
5
Aug
2025
VIDEO: Phil Sharp and Bill Haney on ‘Cracking the Code’
Science and society have always had an uneasy relationship. Yet there are always people out there seeking to build bridges of understanding. I recently moderated a conversation at MIT with Phil Sharp, the Nobel Prize-winning biologist, and Bill Haney, a filmmaker and biotech entrepreneur with Dragonfly Therapeutics and Skyhawk Therapeutics. They collaborated on a documentary film called “Cracking the Code.”... Read More
31
Jul
2025
GSK Doubles Down on China, Sarepta Rebounds, and Frazier’s $1.3B Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jul
2025
Sarepta Crashes, Abivax Soars, & Sanofi Buys Another Vaccine Platform
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jul
2025
Creative Ways to Back Young Scientists: Andy Rachleff and Yung Lie on The Long Run
Yung Lie and Andy Rachleff are today’s guests on The Long Run. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation, based in New York. Andy is the board chair. Andy was one of the founding partners of Benchmark Capital, the prominent Silicon Valley VC firm, and today is the chairman of Wealthfront. This is a... Read More
22
Jul
2025
Avalyn Pharma Gets $100M to Deliver Inhalable Pulmonary Fibrosis Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Jul
2025
Omega Funds, Delivering New Products and Returns, Secures $647M New Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.